APR 10, 2019 10:30 AM PDT

A Sample to Insight Solution for Detection and Classification of Challenging Pathogenic BRCA Mutations

Sponsored by: QIAGEN
Speakers
  • Associate Director Global Product Management NGS, QIAGEN
    Biography
      Dr. Anika Joecker is Associate Director Global Product Management NGS at QIAGEN. She joined CLC bio (now QIAGEN) in 2011 as Senior Bioinformatician/Project & Team Manager and worked since 2013 in product management at QIAGEN - first in Bioinformatics and recently now as product manager of the GeneReader NGS System. Anika Joecker holds a Ph.D. in Biology/Bioinformatics from University of Cologne, Germany, and has worked as Bioinformatics Group Leader at the German Cancer Research Center (Heidelberg, Germany).
    • Principal Genome Scientist, Bioinformatics - Genetic Disease , QIAGEN
      Biography
        Jennifer received a B.S. in Genetics from the University of Connecticut and went on to receive a Ph.D. in Human Genetics at the Johns Hopkins School of Medicine. During her graduate training, she used Ingenuity Pathway Analysis and was so impressed with the tool that she approached QIAGEN for the opportunity to support their bioinformatics portfolio. Currently, she is the lead genome scientist supporting QIAGEN's software solutions for analysis and interpretation of variants implicated in hereditary disease.

      Abstract

      The BRCA1 and BRCA2 genes epitomize the modern understanding of cancer molecular genetics. Today, identifying germline and somatic mutations in BRCA1/2 has become routine practice, especially for hereditary cancer studies. However, the highly-fragmented nature of traditional sample to insight workflows can make the identification and classification of all pathogenic and actionable variants in BRCA1/2 particularly challenging. In this webinar, we explore these challenges and present solutions for streamlined, standardized, and accurate detection, interpretation, and reporting of challenging BRCA mutations, such as exon-level copy number variants (CNVs), splicing variants, and variants in homopolymer regions. 

      In the first half of the webinar, we will introduce a fully-integrated Sample to Insight NGS clinical research workflow for the detection of BRCA1/2 mutations.  Designed as an integrated part of the GeneReader NGS System, the QIAact BRCA1/2 and the BRCA Advanced Panel leverages unique molecular index (UMI) technology to detect single nucleotide variants (SNVs), exon-level CNVs, even those at low-frequency, ensuring consideration of all variants within the sample. 

      In the second half of the webinar, we will present a concordance study demonstrating the accuracy of QIAGEN Clinical Insight (QCI®), QIAGEN’s clinical decision support software for the interpretation and reporting of NGS data. The study compares QCI’s automated variant classification of over 6,000 BRCA1/2 variants to the human-derived variant classifications from expert panels (the ENIGMA consortium and ClinGen). QCI achieves extremely high concordance (99.6%) and provides automated tiered classifications according to all 28 ACMG guidelines with full transparency to the underlying evidence.  


      Learning Objectives: 

      1. QIAGEN’s GeneReader workflows are pre-optimized sample to insight solutions able to overcome the challenges of a fragmented NGS workflow
      2. The BRCA ½ and the BRCA Advanced Panels coupled with the GeneReader enable comprehensive profiling of mutations within BRCA, including challenging mutations such as large Indels and exon-level CNVs, and with UMI technology, even those of low allele frequency
      3. QCI Interpret as part of the GeneReader solution automates variant classification using all 28 ACMG criteria, while transparently providing the supporting evidence for variant assessment
      4. In compelling concordance study, QCI-Interpret used to automatically classify >6000 BRCA1 and BRCA2 variants, demonstrating the extremely high concordance (99.6%) between automated tiered classification with this clinical decision support platform and classifications by a panel of experts. 


      Show Resources
      You May Also Like
      MAY 11, 2021 10:00 AM PDT
      C.E. CREDITS
      MAY 11, 2021 10:00 AM PDT
      Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
      APR 01, 2021 8:00 AM PDT
      C.E. CREDITS
      APR 01, 2021 8:00 AM PDT
      Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
      JUN 09, 2021 7:00 AM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      C.E. CREDITS
      JUN 09, 2021 7:00 AM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
      NOV 16, 2020 8:00 AM PST
      C.E. CREDITS
      NOV 16, 2020 8:00 AM PST
      Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
      DEC 02, 2020 8:00 AM PST
      C.E. CREDITS
      DEC 02, 2020 8:00 AM PST
      DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
      DEC 15, 2020 10:00 AM PST
      C.E. CREDITS
      DEC 15, 2020 10:00 AM PST
      DATE: December 15, 2020 TIME: 10:00am PST Scientists from Thermo Fisher Scientific will walk us through the world of microorganisms. They will discuss their most recent research on viruses,...
      APR 10, 2019 10:30 AM PDT

      A Sample to Insight Solution for Detection and Classification of Challenging Pathogenic BRCA Mutations

      Sponsored by: QIAGEN

      Specialty

      Cancer Research

      Assay Development

      Blood

      Pcr/rt-Pcr/real-Time Pcr

      Dna Sequencing

      Cancer Diagnostics

      Clinical Diagnostics

      Lab Automation

      Next-Generation Sequencing

      Diagnostics

      Clinical Research

      Molecular Diagnostics

      Clinical Genetic Molecular Biologist Scientist (Cgmbs)

      Molecular Biology

      Geography

      North America80%

      Asia20%

      Registration Source

      Website Visitors100%

      Job Title

      Medical Laboratory Technician50%

      Clinical Laboratory Scientist25%

      Scientist25%

      Organization

      Clinical Laboratory60%

      Distribution/sales20%

      Biotech Company20%


      Show Resources
      Loading Comments...
      Show Resources
      Attendees
      • See more